Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory

Objective: To evaluate the incidence and the prevalence of neutralising antibodies (NABs) to three interferon beta (IFNβ) products in patients with multiple sclerosis (MS). Methods: Sera were tested from 125 patients with relapsing-remitting MS. Patients were treated with IFNβ-1b (Betaferon, n = 29) 8 MIU subcutaneously every other day, IFNβ-1a (Avonex, n = 44) 30 μg intramuscularly once weekly, or IFNβ-1a (Rebif, n = 36) 22 μg subcutaneously three times weekly for 6 to 18 months. An additional 16 patients were treated with Rebif 22 μg intramuscularly once or twice weekly. NABs were assessed using the cytopathic effect assay before treatment and every three months during treatment. Patients with two or more consecutive positive samples were considered to be persistent NAB positive (NAB+). Results: At baseline, no patients were NAB+. NABs developed during the first three months of treatment and continued to develop until month 18. Over 18 months of treatment, the risk of being persistent NAB+ was 31% for Betaferon, 15% for Rebif, and 2% for Avonex (Betaferon versus Avonex, p = 0.001; Betaferon versus Rebif, p = 0.19; Rebif versus Avonex, p = 0.04). In all patients with one or more NAB+ samples, the risk of becoming NAB+ was 38% for Betaferon, 18% for Rebif, and 7% for Avonex (Betaferon versus Avonex, p = 0.0007; Betaferon versus Rebif, p = 0.10; Rebif versus Avonex, p = 0.07). At month 18, the prevalence of persistent NAB+ patients was 31.6% for Betaferon, 18.7% for Rebif, and 4% for Avonex. Numbers of NAB+ patients observed were similar with intramuscular Rebif and with subcutaneous Rebif. Conclusion: The three IFNβ preparations have different degrees of immunogenicity, with Betaferon producing the highest incidence of NABs and Avonex the lowest. These differences should be considered by neurologists when selecting treatment for their patients with MS because NABs can reduce both bioavailability and clinical efficacy of IFNβ.

[1]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[2]  A. Pachner.  Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practicing neurologist , 1997, Neurology.

[3]  C. Vedeler,et al.  Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. , 2000, Neurology.

[4]  Y. Kawade.  Quantitation of neutralization of interferon by antibody. , 1986, Methods in enzymology.

[5]  P. Kivisäkk,et al.  Neutralizing and binding anti‐interferon‐β (IFN‐β) antibodies. A comparison between IFN‐β‐1a and IFN‐β‐1b treatment in multiple sclerosis , 2000, European journal of neurology.

[6]  F. H. Garrison,et al.  Garrison's History of Neurology , 1969 .

[7]  R. Knobler,et al.  Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. , 1993, Journal of interferon research.

[8]  M. Reindl,et al.  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.

[9]  M. Biffoni,et al.  Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. , 1997, Cytokines, cellular & molecular therapy.

[10]  Adrian Whitty,et al.  Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.

[11]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[12]  K. Myhr,et al.  Neutralizing antibodies to interferon (IFN) α-2a and IFN β-1a or IFN β-1b in MS are not cross-reactive , 2000, Neurology.

[13]  Y. Kawade.  [74] Quantitation of neutralization of interferon by antibody , 1986 .

[14]  L. Wilkins.  Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b , 1996, Neurology.

[15]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[16]  R. Herndon,et al.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.

[17]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[18]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[19]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[20]  M. Trojano,et al.  Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. , 1999, Neurology.

[21]  C. Pozzilli,et al.  Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b , 1999, Journal of the Neurological Sciences.

[22]  J. Petkau,et al.  Neutralising Antibodies to Interferon-β in the Treatment of Multiple Sclerosis , 1999 .

[23]  L. S. King.  Garrison's History of Neurology , 1969 .

[24]  C. Pozzilli,et al.  Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a , 1998 .

[25]  Richard A. C. Hughes,et al.  PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.

[26]  R. Mutani,et al.  Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. , 2000, Immunopharmacology.

[27]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[28]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[29]  Evidence of interferon β-1a dose response in relapsing-remitting MS , 1999, Neurology.

[30]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[31]  C. Bever,et al.  Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration , 1996, Neurology.

[32]  K. Bendtzen,et al.  Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration , 2000 .

[33]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.